Introduction: What they say
Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.”
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Human Leukemias: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4
From Research findings to Therapeutic opportunity:
This study suggests that LRRC4/NGL-2, by increasing the expression of its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).
Taken together, this study suggests that pharmacological formulations encompassing “LRRC4/NGL-2 activator(s) either alone or in combination with other anticancer drugs“ may be used to inhibit B-Cell and myeloid leukemias.
Details of the research details:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How LRRC4/NGL-2 increases the expression of IRF4?
Amount: $ 100
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Molecular therapy for Human Leukemias: LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2) suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 31/December/2016, 12.16 pm, Genome-2-Bio-Medicine Discovery Center.
Courtesy: When you cite drop us a line at email@example.com